Work disability and state benefit claims in early rheumatoid arthritis : The ERAN cohort by McWilliams, Daniel F. et al.
Original article
Work disability and state benefit claims in early
rheumatoid arthritis: the ERAN cohort
Daniel F. McWilliams1, Sneha Varughese2, Adam Young3, Patrick D. Kiely4 and
David A. Walsh1,2
Abstract
Objective. RA is an important cause of work disability. This study aimed to identify predictive factors for
work disability and state benefit claims in a cohort with early RA.
Methods. The Early RA Network (ERAN) inception cohort recruited from 22 centres. At baseline, and
during each annual visit, participants (n= 1235) reported employment status and benefits claims and how
both were influenced by RA. Survival analysis derived adjusted hazard ratios (aHRs) and 95% CIs to
predict associations between baseline factors and time until loss of employment due to RA or a state
benefits claim due to RA.
Results. At baseline, 47% of participants were employed and 17% reported claiming benefits due to RA.
During follow-up, loss of employment due to RA was reported by 10% (49/475) of the participants and
20% (179/905) began to claim benefits. Independent predictors of earlier work disability were bodily pain
(aHR 2.45, 95% CI 1.47, 4.08, P= 0.001) and low vitality (aHR 1.84, 95% CI 1.18, 2.85, P= 0.007).
Disability (aHR 1.28, 95% CI 1.02, 1.61, P= 0.033), DAS28 (aHR 1.48, 95% CI 1.05, 2.09, P= 0.026)
and extra-articular disease (aHR 1.77, 95% CI 1.17, 2.70, P= 0.007) predicted earlier benefits claims.
Conclusion. Work disability and benefits claims due to RA were predicted by different baseline factors.
Pain and low vitality predicted work disability. Baseline disability, extra-articular disease manifestations
and disease activity predicted new benefits claims due to RA. Future research on interventions targeting
these factors could investigate job retention and financial independence.
Key words: rheumatoid arthritis, employment, social security, work disability.
Introduction
The prevalence of RA in the general population is between
0.5 and 1% with 55% of cases diagnosed at working age
[1, 2]. Working ability is multifactorial; it depends on a
combination of professional skills and physiological and
psychological characteristics in relation to work require-
ments [3]. Work disability is a term used widely in the lit-
erature incorporating reduced work capacity, cessation of
working life and applications for benefits and job loss has
a significant economic burden. Previous studies have
shown that people with RA are more likely to stop work
in comparison to the general population, with one study
reporting a 32-fold increase [4]. In the UK in 2007, the
National RA Society found that 28% of people with RA
in the UK gave up work due to their condition within 12
months [5], and a similar high number was reported in a
subsequent survey in Scotland [6]. Mean annual loss of
productivity due to sick leave in people with RA in
Germany was estimated to be 1417 days [7]. Work dis-
ability rates vary, depending on different cohorts, nation-
alities and definitions used; on average 2040% of
previously employed RA patients become permanently
work disabled within 2 years of diagnosis, with this
increasing to 4080% within 520 years [8]. In the UK
in 2003, 80% of people of working age who received
state incapacity benefits did not return to work [9]. In
2009 the UK government reported that 4.5 million
people were claiming disability benefits at some level
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[10]. Interventions targeted at factors that predispose to
work disability have the potential to ameliorate these
social impacts in early RA.
Within the UK, the most frequent benefits claimed by
patients with RA are the disability living allowance (DLA)
and the employment and support allowance (ESA), previ-
ously known as the incapacity benefit. The DLA is not
means tested or dependent on employment status and
applicants are eligible if problems with mobility or care
have persisted for a minimum of 3 months. The ESA is
means tested; applicants must be <65 years of age, have
finished their statutory sick pay (28 weeks) and must be
self-employed or unemployed with an illness that affects
their ability to work [11, 12]. Additionally, state benefits
may be claimed in the UK for low income, unemployment
and other reasons [13]. Although people with RA may
claim some of these additional benefits, they are often
not considered to be due to RA directly.
Previous reviews have shown that greater disability as
measured by the HAQ and older age is associated with
future work disability in people with RA [7, 14]. However,
only a few studies have tried to identify factors within early
RA [14]. This study aimed to identify potential predictive
factors for job loss and social security benefits claims in
an inception cohort of early RA.
Methods
Patients and recruitment
The Early RA Network (ERAN) inception cohort study
began recruitment in April 2002 and currently recruits
from 22 outpatient centres in the UK and Ireland [15]. By
the end of February 2012, 1235 patients had been re-
cruited following a clinician diagnosis of RA. Data were
collected at baseline, between 3 and 6 months and then
annually from baseline. ERAN centres manage patients
according to local practice. The ERAN study was
approved by the Trent Research Ethics Committee (refer-
ence 01/4/047) and all participants gave signed, informed
consent in accordance with the Declaration of Helsinki.
Data collection
Data collected at baseline and until the most recent
follow-up was used in this study. A clinical interview and
examination was performed at each visit and participants
continued to receive standard care from their rheumatolo-
gists throughout the study. At baseline, clinicians re-
corded standard demographics (age, sex, height and
weight), known extra-articular disease manifestations
[16] and co-morbidities [17]. The presence of erosions at
baseline was identified from radiographs of the hands and
feet. Patients completed the 36-item Short Form (SF-36)
Health Survey for patient-based assessment of quality of
life [18, 19] and the HAQ [20]. At baseline, and during each
annual study visit, patients were asked to report employ-
ment, job loss (including whether they believed the job
loss was due to RA), retirement and whether they were
claiming benefits due to RA (including, but not restricted
to, disability benefits claims). ESR and RF were obtained
from clinical records. Negative or weakly positive results
for RF according to local reference ranges were classified
as seronegative. Using data from the ERAN database, the
28-joint DAS (DAS28)ESR score was derived and the pa-
tient-derived DAS28 (DAS28-P) was calculated for those
with active disease [21]. The DAS28-P is calculated as
the proportion of the DAS28 score that is derived from
the patient-reported components, namely tender joint
counts and patient global health assessments. The
DAS28-P is proposed to be associated with non-inflam-
matory pain mechanisms and central sensitization. The
DAS28-P may represent a component of the pain pheno-
type related to fibromyalgianess that is distinct from cur-
rent pain severity [21]. After data collection it was
determined whether four or more of the 1987 ACR RA
diagnostic criteria were met [22]. The type of employment
at baseline was recorded in the text at the study visit and
coded using the International Standard Classification of
Occupations 2008 (ISCO-08) and classified as heavy
work or non-heavy work (semi-manual or less) according
to a previously published methodology [23]. Current post-
codes were used to estimate the socioeconomic depriv-
ation derived from the UK government’s 2007 rankings
[Index of Multiple Deprivation (IMD) 2007 rankings].
Work disability due to RA
At baseline, participants reported whether they were
working or not. At baseline, participants of working age
were compared with those that reported active employ-
ment. Work disability was defined as the loss of employ-
ment due to RA, and this was specifically reported by
each participant. For the analysis of job loss due to RA
during follow-up, only participants who were working at
baseline were included. At each visit participants indi-
cated if they were still working, stopped temporarily,
were not currently employed or retired. Each participant
also reported whether the loss of employment was due to
RA or not. The time until the first job loss due to RA
(including concurrent job loss due to RA and first retire-
ment) was derived from these data. Temporary sick leave
was not included as a loss of employment, although it was
recorded during data collection. After 2 years of being
classified as temporary sick leave, we included these
people as losing employment. No additional checks
were made by investigators into the claims that RA was
the cause of loss of employment or whether there were
multiple contributing factors.
Benefit claims due to RA
At baseline, participants reported whether they were
claiming benefits due to RA or not. For the analysis of
time until benefits claims, only those participants who
were not claiming at baseline were included. At each
visit participants indicated if they were claiming benefits
due to RA, and the time until the first benefits claim was
derived from these data. The specific benefits being
claimed due to RA were not recorded, and each partici-
pant self-reported the data.
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Statistical analysis
Univariate data analyses were performed using
MannWhitney U-tests, and log-rank or 2 tests were
used for categorical data, to compare baseline factors
between participants with different work and benefit sta-
tuses. Correlations of categorical data were performed
using Spearman’s coefficient. DAS28 scores were classi-
fied into European League Against Rheumatism (EULAR)
disease activity groups (03.19, 3.25.19, 55.2) [24] and
EULAR response groups comparing baseline and 1-year
follow-up [16], and BMI was classified into World Health
Organization (WHO) groups (<25, 2529.9,530) [25]. For
each SF-36 questionnaire subscale (Bodily Pain, Mental
Health, Vitality and Physical Function), the raw scores be-
tween 0 and 100 were used and not normed for age and
gender [19] because these were included as covariates in
the analyses. The eligible populations for the analyses of
loss of employment due to RA and RA benefit claims were
derived and continuous variables were split into quartiles
of increasing severity or magnitude within each group. Up
until Year 2, follow-up times were calculated as the
number of days until an event of interest or right censor-
ship. This was performed to produce accurate estimates
of the influence of short follow-up times. Beyond 2 years,
the year of each annual visit was used. Survival analysis
was performed and Cox regression was used to calculate
hazard ratios (HRs), adjusted HRs (aHRs) and 95% CIs to
examine independent associations of baseline factors
with shorter time until loss of employment due to RA or
a new benefits claim due to RA. Variables included in
multivariable Cox regression models were age, gender
and DAS28, plus any that had an unadjusted P-value
40.100 (only one variable describing smoking, work
demand or disability was included per model). Sensitivity
analyses were performed post hoc to examine the impact
of early loss to follow-up, the inclusion of people from
Ireland and different extra-articular manifestations on our
main analyses. From baseline to 1 year, EULAR response
categories [26] were calculated from people with DAS28
>3.2, the minimum disease activity required to obtain a
good assessment. SPSS version 16 (IBM, Armonk, NY,
USA) was used to perform the analyses and P< 0.05
was statistically significant.
Results
At baseline, participants (n= 1235, 68% female) had a
median [interquartile range (IQR)] age of 58 (4798)
years. Forty-seven per cent reported that they were
employed at baseline. Also 17% of patients (210/1206)
reported claiming benefits due to RA (Table 1). The
initial DMARD treatments were MTX monotherapy in
46% (522/1134), SSZ monotherapy in 31% (351/1134)
and medication in ERAN has been described in more
detail elsewhere [27].
Univariate analyses of baseline characteristics (Table 1)
indicated that non-workers of working age were older and
exhibited more co-morbidities and higher disease activity,
pain and disability as well as lower physical function, vi-
tality and mental health than workers. Non-workers were
also more likely to have a history of smoking, but not to be
current smokers (workers 29% vs non-workers 32%,
P= 0.484). Heterogeneity was seen between benefit
claimants and non-claimants, with regard to age,
TABLE 1 Demographics of the ERAN cohort and subgroups
Baseline variable Whole cohort Working Not working Benefits No benefits
n 1235 567 227 210 974
Age, years 58 (4798) 50 (4257)** 55 (4559) 60 (5069)* 57 (4767)
BMI, kg/m2 26.8 (23.930.4) 26.9 (24.030.3) 26.8 (24.431.8) 26.8 (24.231.4) 26.8 (23.830.2)
Female gender, % 68 66 70 69 68
Smoking history, % 61 58** 70 71** 59
ACR criteria, % 53 49 55 56 53
Seropositive, % 61 63 61 54* 62
Extra-articular disease, % 15 14 18 17 15
Erosions, % 29 27 29 35* 28
Co-morbidity, % 44 39** 49 52** 42
DAS28 4.8 (3.65.8) 4.4 (3.35.5)** 5.2 (4.06.3) 5.17 (4.276.28)** 4.68 (3.525.75)
Symptom duration, months 6 (312) 6 (412) 6 (413) 7 (313) 6 (312)
HAQ 1.0 (0.51.63) 0.9 (0.31.4)** 1.4 (0.81.9) 1.63 (12.13)** 1.0 (0.381.5)
SF-36 Bodily Pain 41 (2262) 41 (3162)** 31 (2251) 31 (2242)** 41 (3162)
SF-36 Physical Function 50 (3075) 60 (4080)** 35 (1565) 30 (1155)** 50 (3275)
SF-36 Vitality 44 (2556) 44 (2556)** 44 (2556) 38 (1950)** 44 (2556)
SF-36 Mental Health 68 (5280) 70 (5580)** 60 (4580) 60 (4876)** 70 (5584)
The demographics of the ERAN cohort are shown with univariate comparisons between each of the subgroups. Values are the
percentage, median (interquartile range) or the number in each subgroup. ACR: 1987 American College of Rheumatology
criteria for RA. Univariate MannWhitney U or 2 tests **P< 0.01 and *P< 0.05, comparing working with not-working partici-
pants (of working age) or those claiming benefits compared with those not on benefits (all ages). Significant differences
between subgroups are highlighted in bold.
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radiographic erosions, co-morbidities, smoking, disease
activity, disability, mental health, pain and vitality.
The median (IQR) follow-up period was 3 (14) years. A
KaplanMeier plot of incident work disability is presented
in Fig. 1A. Ten per cent (49/475) of participants who had
been employed at baseline reported losing their employ-
ment due to RA before their most recent follow-up, and of
these, 53% (26/49) reported losing their job due to RA
within the first 2 years after baseline assessment.
Eighty-four per cent (41/49) of these participants retired
when they lost their job. Of these 49 people, only 5
reported a later return to work during the time captured
during follow-up.
A KaplanMeier plot of incident benefit claims due to
RA is presented in Fig. 1B. Twenty per cent (179/905) of
participants who were not claiming benefits at baseline
began to claim benefits due to RA during follow-up, and
28% (50/179) began within 2 years of baseline. Twenty-
nine participants reported both job loss due to RA and
new benefit claims. Fourteen participants reported job
loss due to RA without benefit claims, and six people re-
ported job loss but had missing benefits data. The major
DMARDs initiated first (monotherapies of HCQ, SSZ, MTX
or combination therapies including MTX) were not asso-
ciated with times until work disability (2 = 3.3, df = 3,
P= 0.354) or benefits claims due to RA (2 = 1.1, df = 3,
P= 0.775)
Table 2 displays survival analysis using Cox regression
analyses for baseline factors associated with earlier time
until work disability (job loss due to RA). Unadjusted HRs
showed that increased disease activity, disability (HAQ),
bodily pain, smoking, low vitality and poorer mental health
were associated with earlier work disability. Additionally,
univariate log-rank tests stratified by the ERAN study
centre did not find significant heterogeneity between
sites (2 = 11.1, df = 15, P= 0.748). After adjustment, inde-
pendent predictors for earlier work disability were worse
bodily pain and low vitality. Sensitivity analyses that
excluded people with a short (41 year) follow-up or that
excluded people from Ireland (n= 28) did not remove the
statistical significance of bodily pain or vitality (data not
shown).
The survival analysis presented in Table 3 shows the
associations between baseline factors and earlier benefit
claims due to RA. HAQ disability, disease activity, extra-
articular disease, lower vitality, worse bodily pain, poorer
mental health and meeting 1987 ACR criteria were asso-
ciated with earlier benefit claims. Additionally, univariate
log-rank tests stratified by the ERAN study centre did not
find significant heterogeneity between sites (2 = 22,
df = 15, P= 0.102). After adjustments, independent pre-
dictors of earlier benefits claims were DAS28, HAQ dis-
ability and extra-articular disease. The most common
extra-articular disease manifestations [nodules (n= 65),
Sjo¨gren’s syndrome (n= 17) and Raynaud’s disease
(n= 36)] were each analysed separately. Reported nodules
at baseline were significantly associated with the first RA
benefits claim before (HR 1.74, 95% CI 1.12, 2.73,
P= 0.015) and after adjustment for the same confounders
(aHR 1.92, 95% CI 1.13, 3.26, P= 0.016). Sjo¨gren’s syn-
drome and Raynaud’s disease did not show significant
associations with benefits claims due to RA at either
level (data not shown). None of these three extra-articular
manifestations were significantly associated with RA job
loss (data not shown). Additionally, excluding people from
Ireland did not remove the statistical significance of the
DAS28, HAQ and extra-articular manifestations (data not
shown).
Patients with a baseline DAS28 >3.2 (the lowest DAS28
value where a good EULAR response was possible) were
FIG. 1 KaplanMeier plots for times until work disability
and first benefits claims due to RA.
KaplanMeier survival plots of (A) RA work disability and
(B) new benefits claims due to RA. Exact follow-up times
were calculated until Year 2, after which data were col-
lated yearly.
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TABLE 3 Predictors for new benefits claims due to RA
Unadjusted Adjusted
Baseline variable HR (95% CI) P-value aHR (95% CI) P-value
Age Quartiles 1.03 (0.90, 1.18) 0.628 1.00 (0.83, 1.19) 0.966
Gender Female 1.30 (0.93, 1.80) 0.126 1.30 (0.85, 2.00) 0.233
BMI WHO groups 1.21 (0.99, 1.47) 0.057 1.08 (0.84, 1.37) 0.631
High deprivation Top quartile 1.07 (0.55, 2.09) 0.835 Not used
Heavy work Y/N 1.63 (1.03, 2.58)* 0.039 0.97 (0.56, 1.68) 0.912
Ever smoked? Y/N 1.30 (0.96, 1.78) 0.091 1.28 (0.87, 1.89) 0.204
Current smoker Y/N 1.24 (0.79, 1.96) 0.347 Not used
DAS28 EULAR groups 1.38 (1.24, 1.53)* <0.001 1.48 (1.05, 2.09)* 0.026
1987 ACR criteria Y/N 1.76 (1.29, 2.41)* <0.001 1.20 (0.78, 1.85) 0.398
Seropositive Y/N 1.12 (0.80, 1.55) 0.518 Not used
Symptom duration Quartiles 0.93 (0.81, 1.07) 0.328 Not used
Extra-articular disease Y/N 1.53 (1.07, 2.20)* 0.020 1.77 (1.17, 2.70)* 0.007
Disability (HAQ) Quartiles 1.66 (1.43, 1.94)* <0.001 1.28 (1.02, 1.61)* 0.033
SF-36 Bodily Pain Quartiles 1.60 (1.36, 1.89)* <0.001 1.08 (0.84, 1.37) 0.564
SF-36 Vitality Quartiles 1.38 (1.19, 1.59)* <0.001 1.07 (0.87, 1.31) 0.514
SF-36 Mental Health Quartiles 1.33 (1.15, 1.53)* <0.001 1.08 (0.88, 1.33) 0.480
Co-morbidities Y/N 1.34 (1.00, 1.81) 0.052 1.19 (0.81, 1.74) 0.385
DAS28-P Quartiles 1.13 (0.95, 1.34) 0.164 Not used
Cox regression analyses for baseline variables associated with shorter times until first RA benefits claims. Unadjusted ana-
lyses were performed for each variable. Important demographics, age, gender, DAS28 and others that were close to signifi-
cance were selected for the multivariable cox regression. HRs and aHRs are presented with 95% CIs and P-values.
*Significant results.
TABLE 2 Predictors for loss of employment due to RA
Unadjusted Adjusted
Baseline variable HR (95% CI) P-value aHR (95% CI) P-value
Age Quartiles 1.30 (0.98, 1.71) 0.067 1.25 (0.88, 1.76) 0.209
Gender Female 0.86 (0.53, 1.71) 0.860 1.21 (0.53, 2.75) 0.647
BMI WHO groups 1.31 (0.90, 1.90) 0.161 Not used
High deprivation Top quartile 1.21 (0.50, 2.89) 0.673 Not used
Manual work Y/N 1.83 (1.01, 3.31)* 0.046 Not used
Heavy work Y/N 1.97 (1.07, 3.62)* 0.030 1.27 (0.57, 2.84) 0.559
Ever smoked? Y/N 2.36 (1.25, 4.46)* 0.008 1.91 (0.89, 5.76) 0.096
Current smoker Y/N 1.42 (0.77, 2.61) 0.264 Not used
DAS28 EULAR groups 1.82 (1.17, 2.85)* 0.008 0.96 (0.53, 1.74) 0.901
1987 ACR criteria Y/N 1.30 (0.73, 2.31) 0.373 Not used
Seropositive Y/N 0.61 (0.33, 1.12) 0.113 Not used
Symptom duration Quartiles 0.81 (0.61, 1.08) 0.147 Not used
Extra-articular disease Y/N 1.60 (0.80, 3.23) 0.187 Not used
Disability (HAQ) Quartiles 1.69 (1.25, 2.28)* 0.001 0.93 (0.60, 1.44) 0.744
SF-36 Bodily Pain Quartiles 2.63 (1.76, 3.92)* <0.001 2.45 (1.47, 4.08)* 0.001
SF-36 Vitality Quartiles 1.84 (1.34, 2.53)* <0.001 1.84 (1.18, 2.85)* 0.007
SF-36 Mental Health Quartiles 1.34 (1.00, 1.79)* 0.050 0.80 (0.53, 1.19) 0.266
Co-morbidities Y/N 1.24 (0.69, 2.23) 0.464 Not used
DAS28-P Quartiles 1.03 (0.77, 1.39) 0.842 Not used
Cox regression analyses for baseline variables associated with shorter times until loss of employment due to RA. Unadjusted
analyses were performed for each variable. Important demographics, age, gender, DAS28 and others that were close to
significance were selected for the multivariable cox regression. HRs and aHRs are presented with 95% CIs and P-values.
ACR: 1987 American College of Rheumatology criteria for RA. *Significant results.
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categorized into good, moderate and no response ac-
cording to EULAR response criteria at 1 year [26]. New
work disability was found in 9% (7/74) of good, 18% (9/51)
of moderate and 13% (10/76) of no response participants
at 1 year (2 = 1.8, P= 0.406). The trend for EULAR re-
sponse to predict work disability was not significant
(r= 0.05, P= 0.510). New benefits claims due to RA were
found in 17% (20/121) of good, 27% (33/121) of moderate
and 31% (49/157) of no response participants at 1 year
(2 = 8.1, P= 0.018). Better EULAR response was asso-
ciated with a lower probability of new benefits claims
(r= 0.14, P= 0.007).
Discussion
We found that baseline factors that most strongly pre-
dicted work disability due to RA were bodily pain and vi-
tality. These are symptoms that may respond poorly to
traditional medical treatments that focus on disease ac-
tivity, and additional symptom-focused treatments may
have the potential to facilitate job retention. We have pre-
viously shown that reported pain remains high during
follow-up of people with early RA in the ERAN cohort
[28], and factors such as central sensitization in addition
to inflammatory disease activity may contribute to poor
pain outcomes [21]. Other studies have also demon-
strated an increased risk of work disability due to
increased bodily pain [29] and that the SF-36 Bodily
Pain subscale predicted continuous 1-year sick leave in
people with musculoskeletal pain [30]. Low vitality may be
related to greater fatigue and less desire to continue work-
ing [31], and pain and fatigue contribute substantially to
physical disability in RA [32], providing plausible explan-
ations for associations with work disability. Often work
disability can occur within the early years from diagnosis
[33] and people who lose their jobs are unlikely to return to
work [34]. We found that 53% (26/49) of people that re-
ported work disability due to RA did so within 2 years.
Greater attention to the alleviation of pain and fatigue in
the management of early RA may facilitate job retention.
An association between the SF-36 Mental Health sub-
scale and work disability was demonstrated in one study
of RA [35], but we and another study [36] found that any
such association was not independent of other covariates.
Older age [37], HAQ disability [4, 23, 34] and physically
demanding employment [8, 23, 34] have each been re-
ported to be associated with work disability in previous
studies [38]. Greater self-reported disability may be ex-
pected to make continuing employment more difficult,
either because of physically demanding jobs, difficult
commutes [5, 6, 39] or lack of support [5, 6]. However,
in the ERAN cohort, adjustments for other confounders
removed the statistical significance from these factors in
our survival analysis, implying a lesser risk from them than
from pain and low vitality. Geographical influences may
account for differences in work disability across studies,
as rates can vary between countries [40], and most of the
literature regarding work disability in RA comes from
countries other than the UK. It is worth noting that loss
of employment due to RA does not always correspond
with a new benefits claim. Some benefits may be claimed
by those in work (due to disability or low-income employ-
ment); also some people leaving work due to RA might not
consider their subsequent benefits claims as being due to
RA. Benefits for supplementing income might not be re-
ported to ERAN investigators as due to RA, or may not be
claimed by all eligible participants.
Baseline factors that most strongly predicted benefits
claims due to RA were disease activity, greater disability
and the presence of extra-articular disease. The
association of benefit claims with baseline extra-articular
disease was not explained by greater disability, nor by
higher disease activity scores, as it persisted despite ad-
justment for other factors. Further research is required to
determine whether extra-articular disease influences the
likelihood that people with RA will apply for benefits or
whether it has an influence on the likelihood that benefits
will be awarded. When rheumatoid nodules, Sjo¨gren’s
syndrome and Raynaud’s disease were modelled separ-
ately, only nodules continued to show a significant asso-
ciation with benefits claims due to RA. However, nodules
were the most frequently noted extra-articular features,
and our study may not have had sufficient power to
detect associations with less common manifestations.
Other studies have reported associations between func-
tional capacity and disability payments [4, 14, 41]. The
association with baseline HAQ may be expected, as bene-
fits are dependent on the extent of reported disability.
Our data provide some evidence that achieving better
EULAR response improves the likelihood that people with
RA will not subsequently claim benefits. Interpretation of
the lack of observed statistical association between
EULAR response and job loss is limited by the small
number of participants that could be included in the ana-
lysis. Previous studies have demonstrated that treatments
that improve inflammatory disease activity in RA can
reduce time away from work [42], and further research is
necessary to determine the extent to which improved
disease-modifying strategies could further reduce work
disability compared with the contemporary practice rep-
resented by the ERAN cohort.
We present evidence that different baseline factors pre-
dict job loss and benefit claims. In particular, both in un-
adjusted and adjusted analyses, bodily pain predicted
loss of employment more strongly than it predicted new
benefits claims. Loss of employment and new benefits
claims represent distinct aspects of work disability and
different strategies may need to be adopted to reduce
their impact. Attention to the pain experienced by
people with early RA may have a particular impact on
job retention.
Data on education level are not available for the ERAN
cohort, but may contribute to success in benefits claims.
For example, the ability to complete forms or to appeal
adverse benefits decisions may influence the success of
benefits claims. Education level may also affect job loss
and benefits claims by determining employment type and
flexibility or contributing to social deprivation. However,
we found that high socioeconomic deprivation and
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manual work were not specifically associated with loss of
employment or new benefits claims due to RA. ERAN re-
cruited from diverse regions of the UK and also from
Ireland. However, we did not find evidence that regional
variations influenced our findings. No significant hetero-
geneity was detected between ERAN centres at the uni-
variate level for time until job loss due to RA and benefits
claims due to RA, and exclusion of Ireland in our sensitiv-
ity analyses did not affect our results. One strength of the
ERAN study was that participants were specifically asked
to assign a reason for loss of employment, which allowed
us to determine work disability due to RA rather than job
loss. The predictors of work disability and benefits claims
in this study are all readily measured in ordinary clinical
settings and could be used routinely. Limitations of this
study include the relatively short follow-up and that self-
reported information was not verified independently. The
UK benefits system requires access to information con-
tained within medical records to validate the process of
benefit award, and responses to self-report question-
naires may be influenced by a desire to facilitate potential
claims. The data do not identify the type of benefit claimed
and our research relied on participants’ self-reported re-
lationship between benefits claims and RA. Further re-
search is required to fully explore the possibly complex
interactions between RA and other factors that may me-
diate job loss and benefits claims and would ideally in-
clude both qualitative and quantitative methodologies and
data from a variety of sources. A proportion of participants
may not have applied for social security benefits because
of financial security, lack of information or because of
negative perceptions of benefit claims. Factors that influ-
ence benefit claims in the UK (and Ireland) may not be
generalizable to other populations. A greater proportion
of people with RA claim benefits in European vs North
American studies, possibly due to greater accessibility
to welfare facilities within Europe and different insurance
systems [40, 43, 44].
In conclusion, work disability is a major issue for
people with early RA, as manifested by high job loss
and benefits claims. Work disability and benefits claims
are common in people with newly diagnosed RA. Different
baseline factors predict job loss or benefits claims, with
pain being a major predictor of subsequent job loss.
Greater attention to work disability during the initial as-
sessment of people with RA could lead to interventions
that reduce its impact in later disease. Attention to factors
such as pain, vitality and reported disability, as well as
inflammatory disease activity, has the potential to
reduce subsequent work disability in people presenting
with early RA.
Rheumatology key messages
. More pain and less vitality at baseline predicted job
loss due to RA.
. Disability, higher DAS28 and extra-articular mani-
festations predicted new state benefits claims due
to RA.
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